{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:03:07Z","timestamp":1784134987274,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Cape Town"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data on the natural history of untreated hepatocellular carcinoma (HCC) are limited and derive mostly from patients in untreated arms of randomised control trials, conducted in high income countries. In this study, we determined the natural history of untreated HCC and identify predictors of survival in a predominantly SSA cohort of patients managed at Groote Schuur Hospital, Cape Town, South Africa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 35-year retrospective cohort study of 469 patients with untreated HCC managed at Groote Schuur Hospital, Cape Town, South Africa from 1990 to 2025 was conducted. Demographics, clinical features, laboratory data, radiological findings and survival were analysed. Multivariate Cox regression identified independent predictors of mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort comprised 347 (74%) men, with a median age of 48 [19\u201389] years. The majority (380\/469, 81.0%) were from South Africa, while the remaining 89 patients originated mostly from other neighbouring SSA countries. Chronic hepatitis B virus (HBV) infection was the leading aetiology (53.3%). Most (96.3%) presented with advanced disease (BCLC stage C or D), with high rates of multifocal tumours (69.1%), portal vein tumour thrombosis (38.8%) and extrahepatic metastases (32.6%). The median overall survival was 36.5 days and the one, six and 12-month survival rates were 59.8%, 14.4% and 7.6% respectively. Independent predictors of mortality included poor performance status, elevated alpha-fetoprotein levels, hypoalbuminemia, higher CTP grade, elevated MELD-Na and advanced BCLC stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Untreated HCC in sub-Saharan Africa is marked by advanced presentation and aggressive disease with rapid clinical deterioration and poor long-term survival. This study highlights the critical need for earlier diagnosis, HBV prevention and the development of accessible, early context-appropriate palliative care interventions in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01414-0","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T11:13:45Z","timestamp":1771586025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Natural History and Prognostic Determinants of Untreated Hepatocellular Carcinoma in a Sub-Saharan African Cohort"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2148-685X","authenticated-orcid":false,"given":"Sanju","family":"Sobnach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1405-474X","authenticated-orcid":false,"given":"Urda","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-301X","authenticated-orcid":false,"given":"C. Wendy","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7128-8329","authenticated-orcid":false,"given":"Mark W.","family":"Sonderup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2783-3267","authenticated-orcid":false,"given":"Inae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-1756","authenticated-orcid":false,"given":"Keith","family":"Venter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-500X","authenticated-orcid":false,"given":"Ren\u00e9","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Emmamally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-8548","authenticated-orcid":false,"given":"Marc","family":"Bernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-9032","authenticated-orcid":false,"given":"Tinus","family":"du Toit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-9508","authenticated-orcid":false,"given":"Luiz F.","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-256X","authenticated-orcid":false,"given":"Eduard","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"3","key":"1414_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10360","key":"1414_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362.","journal-title":"Lancet"},{"issue":"1","key":"1414_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/030089160909500104","volume":"95","author":"C Bosetti","year":"2009","unstructured":"Bosetti C, Bianchi C, Negri E, Colombo M, La Vecchia C. Estimates of the incidence and prevalence of hepatocellular carcinoma in Italy in 2002 and projections for the years 2007 and 2012. Tumori. 2009;95(1):23\u20137.","journal-title":"Tumori"},{"issue":"9822","key":"1414_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245\u201355.","journal-title":"Lancet"},{"issue":"3","key":"1414_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"11","key":"1414_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S2468-1253(22)00042-5","volume":"7","author":"E Jonas","year":"2022","unstructured":"Jonas E, Bernon M, Robertson B, Kassianides C, Keli E, Asare KO, et al. Treatment of hepatocellular carcinoma in sub-Saharan africa: challenges and solutions. Lancet Gastroenterol Hepatol. 2022;7(11):1049\u201360.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1414_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.hpb.2023.09.015","volume":"26","author":"S Sobnach","year":"2024","unstructured":"Sobnach S, Kotze U, Spearman CW, Sonderup M, Nashidengo PR, Ede C, et al. The management and outcomes of hepatocellular carcinoma in sub-Saharan africa: a systematic review. HPB (Oxford). 2024;26(1):21\u201333.","journal-title":"HPB (Oxford)"},{"issue":"5","key":"1414_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","volume":"164","author":"MR Toh","year":"2023","unstructured":"Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PK, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164(5):766\u201382.","journal-title":"Gastroenterology"},{"issue":"6","key":"1414_CR9","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606.","journal-title":"J Hepatol"},{"issue":"1","key":"1414_CR10","first-page":"25","volume":"38","author":"IO Olubuyide","year":"1992","unstructured":"Olubuyide IO. The natural history of primary liver cell carcinoma: a study of 89 untreated adult Nigerians. Cent Afr J Med. 1992;38(1):25\u201330.","journal-title":"Cent Afr J Med"},{"issue":"11","key":"1414_CR11","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S2468-1253(22)00041-3","volume":"7","author":"CW Spearman","year":"2022","unstructured":"Spearman CW, Dusheiko G, Jonas E, Abdo A, Afihene M, Cunha L, et al. Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2022;7(11):1036\u201348.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1414_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S2468-1253(16)30161-3","volume":"2","author":"JD Yang","year":"2017","unstructured":"Yang JD, Mohamed EA, Aziz AO, Shousha HI, Hashem MB, Nabeel MM, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in africa: a multicountry observational study from the Africa liver cancer consortium. Lancet Gastroenterol Hepatol. 2017;2(2):103\u201311.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1414_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the L","year":"2025","unstructured":"European Association for the Study of the L. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"issue":"12","key":"1414_CR14","first-page":"751","volume":"13","author":"JK Heimbach","year":"2017","unstructured":"Heimbach JK. Overview of the updated AASLD guidelines for the management of HCC. Gastroenterol Hepatol (N Y). 2017;13(12):751\u20133.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"7","key":"1414_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/apt.12450","volume":"38","author":"D Tan","year":"2013","unstructured":"Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the united States. Aliment Pharmacol Ther. 2013;38(7):703\u201312.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1414_CR16","doi-asserted-by":"publisher","first-page":"e0246143","DOI":"10.1371\/journal.pone.0246143","volume":"16","author":"YA Kim","year":"2021","unstructured":"Kim YA, Kang D, Moon H, Sinn D, Kang M, Woo SM, et al. Survival in untreated hepatocellular carcinoma: A National cohort study. PLoS ONE. 2021;16(2):e0246143.","journal-title":"PLoS ONE"},{"issue":"1","key":"1414_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40273-013-0109-7","volume":"32","author":"FT Shaya","year":"2014","unstructured":"Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare. PharmacoEconomics. 2014;32(1):63\u201374.","journal-title":"PharmacoEconomics"},{"issue":"8","key":"1414_CR18","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1053\/j.gastro.2017.02.040","volume":"152","author":"M Serper","year":"2017","unstructured":"Serper M, Taddei TH, Mehta R, D\u2019Addeo K, Dai F, Aytaman A, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152(8):1954\u201364.","journal-title":"Gastroenterology"},{"key":"1414_CR19","doi-asserted-by":"publisher","first-page":"1142661","DOI":"10.3389\/fonc.2023.1142661","volume":"13","author":"MJ Kwon","year":"2023","unstructured":"Kwon MJ, Chang S, Kim JH, Han JW, Jang JW, Choi JY, et al. Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: an analysis of nationwide data. Front Oncol. 2023;13:1142661.","journal-title":"Front Oncol"},{"key":"1414_CR20","first-page":"3","volume":"2","author":"AA Zeeneldin","year":"2015","unstructured":"Zeeneldin AA, Salem SE, Darwish AD, El-Gammal MM, Hussein MM, Saadeldin M. Untreated hepatocellular carcinoma in egypt: outcome and prognostic factors. J Hepatocell Carcinoma. 2015;2:3\u20139.","journal-title":"J Hepatocell Carcinoma"},{"key":"1414_CR21","unstructured":"Swedish liver cancer registry. Proportion of patients with HCC undergoing palliative treatment who receive best supportive care only-intended intervention 2009\u20132023. https:\/\/statistik.incanet.se\/SweLiv\/. Accessed 21 June 2025."},{"issue":"5","key":"1414_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/cncr.25683","volume":"117","author":"SA Shah","year":"2011","unstructured":"Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117(5):1019\u201326.","journal-title":"Cancer"},{"issue":"1","key":"1414_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/hep.1840160122","volume":"16","author":"L Barbara","year":"1992","unstructured":"Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16(1):132\u20137.","journal-title":"Hepatology"},{"issue":"9","key":"1414_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4254\/wjh.v4.i9.256","volume":"4","author":"G Cabibbo","year":"2012","unstructured":"Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol. 2012;4(9):256\u201361.","journal-title":"World J Hepatol"},{"issue":"3","key":"1414_CR25","first-page":"303","volume":"12","author":"D Flook","year":"1986","unstructured":"Flook D, Hughes LE, Williams GT. Prolonged survival without treatment in a patient with primary hepatocellular carcinoma. Eur J Surg Oncol. 1986;12(3):303\u20136.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"1414_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/hep.27443","volume":"61","author":"EG Giannini","year":"2015","unstructured":"Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184\u201390.","journal-title":"Hepatology"},{"issue":"7","key":"1414_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.17235\/reed.2025.11029\/2024","volume":"117","author":"H Gonz\u00e1lez-S\u00e1nchez","year":"2025","unstructured":"Gonz\u00e1lez-S\u00e1nchez H, Casta\u00f1o-Garc\u00eda A, Celada-Sendino M, Fl\u00f3rez-D\u00edez P, Garc\u00eda-Calonge M, Rodr\u00edguez M, et al. Demographic and survival characteristics of untreated hepatocellular carcinoma patients: insights into the natural history and prognostic determinants. Rev Esp Enferm Dig. 2025;117(7):366\u201373. https:\/\/doi.org\/10.17235\/reed.2025.11029\/2024.","journal-title":"Rev Esp Enferm Dig"},{"issue":"2","key":"1414_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cgh.2016.07.033","volume":"15","author":"N Khalaf","year":"2017","unstructured":"Khalaf N, Ying J, Mittal S, Temple S, Kanwal F, Davila J, et al. Natural history of untreated hepatocellular carcinoma in a US cohort and the role of cancer surveillance. Clin Gastroenterol Hepatol. 2017;15(2):273\u201381.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1414_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3904\/kjim.1989.4.2.136","volume":"4","author":"UB Kim","year":"1989","unstructured":"Kim UB, Doo CJ, Baek SH, Kim JH, Lee HB, Park SK, et al. Natural history and prognostic factors of primary hepatocellular carcinoma: study of 70 untreated patients. Korean J Intern Med. 1989;4(2):136\u201341.","journal-title":"Korean J Intern Med"},{"issue":"10","key":"1414_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/00042737-199710000-00011","volume":"9","author":"EA Kouroumalis","year":"1997","unstructured":"Kouroumalis EA, Skordilis PG, Moschandrea J, Alexandrakis G, Charoulakis N, Tzardi M, et al. Natural history of advanced hepatocellular carcinoma in Crete. Association with hepatitis C virus. Eur J Gastroenterol Hepatol. 1997;9(10):981\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"1414_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62\u20137.","journal-title":"Hepatology"},{"issue":"4","key":"1414_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1046\/j.1440-1746.2002.02734.x","volume":"17","author":"K Okuda","year":"2002","unstructured":"Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol. 2002;17(4):401\u20135.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1414_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00000421-199808000-00014","volume":"21","author":"A Pawarode","year":"1998","unstructured":"Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998;21(4):386\u201391.","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"1414_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/j.1572-0241.2005.00229.x","volume":"100","author":"YP Yeung","year":"2005","unstructured":"Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005;100(9):1995\u20132004.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1414_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"20","key":"1414_CR36","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"1","key":"1414_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/wber\/lhab012","volume":"36","author":"A Chatterjee","year":"2022","unstructured":"Chatterjee A, Czajka L, Gethin A. Wealth inequality in South Africa, 1993\u20132017. World Bank Econ Rev. 2022;36(1):19\u201336.","journal-title":"World Bank Econ Rev"},{"issue":"1","key":"1414_CR38","doi-asserted-by":"publisher","first-page":"28865","DOI":"10.3402\/gha.v8.28865","volume":"8","author":"JE-O Ataguba","year":"2015","unstructured":"Ataguba JE-O, Day C, McIntyre D. Explaining the role of the social determinants of health on health inequality in South Africa. Global Health Action. 2015;8(1):28865.","journal-title":"Global Health Action"},{"issue":"5","key":"1414_CR39","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/wjs.12559","volume":"49","author":"S Sobnach","year":"2025","unstructured":"Sobnach S, Emmamally M, Venter K, Krige J, Bernon M, Kloppers C, et al. Healthcare Disparities in the Treatment and Outcomes of Hepatocellular Carcinoma in South Africa. World J Surg. 2025;49(5):1290\u201397. https:\/\/doi.org\/10.1002\/wjs.12559.","journal-title":"World J Surg"},{"issue":"2","key":"1414_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"4","key":"1414_CR41","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"L European Organisation For","year":"2012","unstructured":"European Association For The Study Of The, European Organisation For L, Treatment Of R. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u201343.","journal-title":"J Hepatol"},{"issue":"1","key":"1414_CR42","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","journal-title":"Hepatology"},{"key":"1414_CR43","doi-asserted-by":"crossref","unstructured":"Emmamally M, Kotze U, Bernon M, Robertson B, Khan R, Sobnach S, et al. The spectrum and outcome of metastatic hepatocellular carcinoma in a South African patient cohort. HPB (Oxford); 2025.","DOI":"10.1016\/j.hpb.2025.01.001"},{"issue":"4","key":"1414_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.patbio.2010.01.005","volume":"58","author":"MC Kew","year":"2010","unstructured":"Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58(4):273\u20137.","journal-title":"Pathol Biol (Paris)"},{"issue":"3","key":"1414_CR45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jvh.12043","volume":"20","author":"MC Kew","year":"2013","unstructured":"Kew MC. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J Viral Hepat. 2013;20(3):149\u201357.","journal-title":"J Viral Hepat"},{"key":"1414_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/JHC.S44381","volume":"1","author":"MC Kew","year":"2014","unstructured":"Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma. 2014;1:115\u201325.","journal-title":"J Hepatocell Carcinoma"},{"issue":"9","key":"1414_CR47","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/jmv.21574","volume":"81","author":"R Viana","year":"2009","unstructured":"Viana R, Wang R, Yu MC, Welschinger R, Chen CY, Kew MC. Hepatitis B viral loads in Southern African Blacks with hepatocellular carcinoma. J Med Virol. 2009;81(9):1525\u201330.","journal-title":"J Med Virol"},{"issue":"5","key":"1414_CR48","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/MEG.0b013e3283344991","volume":"22","author":"R Welschinger","year":"2010","unstructured":"Welschinger R, Kew MC, Viana R, Badri M. T1653 mutation in the enhancer II region of the hepatitis B virus genome in Southern African Blacks with hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22(5):541\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"1414_CR49","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01414-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01414-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01414-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:33:35Z","timestamp":1781634815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01414-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01414-0","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the institutional review board of the Faculty of Health Sciences at the University of Cape Town (IRB00001938, HREC REF 331\/2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interest"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}